Myovant Sciences

Myovant Sciences

World Rank (Jan-05-2024)
4,776
World Rank (Jul-30-2023)
4,776
Market Cap (Jul-30-2023)
2.620 Billion USD
World Rank (Jan-07-2022)
8,121
Market Cap (Jan-07-2022)
1.291 Billion USD
World Rank (Jan-01-2021)
4,805
Market Cap (Jan-01-2021)
2.502 Billion USD
Company Rank in Country in 2023
Company rank in UK in July-2023 is 167
Headquarters Country
UK
World Region
Europe
World Subregion
Northern Europe
Annual Revenue in USD
271 Million USD
Annual Net Income in USD
-241 Million USD
Annual Results for Period Ending
Mar-2022 ending year
Total Assets in USD
612 Million USD
Total Liabilities in USD
1,170 Million USD
Total Equity in USD
-557 Million USD
Balance Sheet for Period Ending
Mar-2022 ending year
Business Sector
Healthcare
HealthCare Products
Biotechnology
Biopharmaceutical
Company Website
MYOVANT SCIENCES LTD.
Company Profile

Myovant Sciences is a biopharmaceutical company. It works for women and for men through purpose driven science, Empowering Medicines and Transformative Advocacy company. It have three clinical programs for relugolix which consisted of five international phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis associated pain and one in men with advanced prostate cancer. The headquarters is in UK.

Sumitovant Biopharma acquired Myovant Sciences for 1.7 billion USD in 2023.

IPO Year
2016
Company SubCategory
Top Healthcare Companies in UK
Top Healthcare Companies in Europe

Share